Clinical Trial Update: Study to Assess Safety and Efficacy of Kabiven® in Pediatric Patients 2 to 16 Years of Age [Phase 4]

View source ↗

Summary

A Phase 4 pediatric trial evaluating safety and efficacy of Kabiven in children aged 2 to 16 with malnutrition has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malnutrition

Drugs mentioned

• KABIVEN

Snippet

Sponsor: Fresenius Kabi | Conditions: Malnutrition | Phase 4 | Status: WITHDRAWN